US 11,752,344 B2
Synchronization of anti-tachycardia pacing in an extra-cardiovascular implantable system
Troy E. Jackson, Rogers, MN (US)
Assigned to Medtronic, Inc., Minneapolis, MN (US)
Filed by Medtronic, Inc., Minneapolis, MN (US)
Filed on May 18, 2021, as Appl. No. 17/323,008.
Application 17/323,008 is a continuation of application No. 15/071,231, filed on Mar. 16, 2016, granted, now 11,027,132.
Prior Publication US 2021/0275809 A1, Sep. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 1/362 (2006.01); A61N 1/39 (2006.01); A61B 5/00 (2006.01); A61B 5/363 (2021.01); A61N 1/365 (2006.01); A61N 1/05 (2006.01)
CPC A61N 1/3621 (2013.01) [A61B 5/363 (2021.01); A61B 5/4836 (2013.01); A61N 1/36514 (2013.01); A61N 1/3956 (2013.01); A61N 1/3962 (2013.01); A61N 1/3987 (2013.01); A61N 1/0504 (2013.01); A61N 1/0563 (2013.01); A61N 1/3622 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A medical device, comprising:
a sensing circuit configured to:
receive a first cardiac electrical signal; and
sense first cardiac events each associated with a myocardial depolarization from the first cardiac electrical signal;
a control circuit coupled to the sensing circuit and configured to:
detect tachycardia from the first cardiac electrical signal;
set an ATP interval; and
set a first extended ATP interval that is longer than the ATP interval; and
a therapy delivery circuit coupled to the control circuit and configured to deliver a first therapy following the detection of the tachycardia by the control circuit by:
delivering a first leading ATP pulse at the first extended ATP interval from a first one of the first cardiac events sensed by the sensing circuit from the first cardiac electrical signal; and
delivering a second ATP pulse at the ATP interval from the first leading ATP pulse.